2010 Fiscal Year Final Research Report
Development of the molecular target therapy for oral squamous cell carcinoma by tumor angiogenesis inhibit.
| Project/Area Number |
21890168
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Surgical dentistry
|
|---|
| Research Institution | Yamaguchi University |
|---|
Principal Investigator |
ITASHIKI Yasutaka Yamaguchi University, 医学部附属病院, 医員研究 (70530236)
|
|---|
| Project Period (FY) |
2009 – 2010
|
| Keywords | Bevacizumab / S-1 / 血管新生阻害 / アポトーシス |
|---|
| Research Abstract |
Because the combination of bevacizumab and S-1 which was a 5-FU-based anticancer agent which was the molecular target drug of the vascularization repressor showed a significant antitumor effect in the implanted nude mouse of the oral squamous cell carcinoma cell, HSC-2, it was suggested that it was with new Tumor dormancy therapy for oral cancer.
|
